

2020 Annual General Meeting – Key Dates

25 September 2020 - AusCann Group Holdings Limited (ASX: AC8) ('AusCann' or 'the Company') announces that its Annual General Meeting will be held on Friday, 20 November 2020 at 11.00am (WST) at the Perth Convention and Exhibition Centre, 21 Mounts Bay Road, Perth, Western Australia.

In accordance with ASX Listing Rule 3.13.1 and clause 12.6 of the Company's Constitution, a valid nomination for the position of Director must be received by the Company not less than 35 business days before the date of the annual general meeting (being Thursday, 1 October 2020).

Further information on the Annual General Meeting will be provided in the Notice of Annual General Meeting which will be released to ASX on or before Monday, 19 October 2020.

ENDS

This ASX announcement was authorised for release by the Board of AusCann.

For more information, please contact:

Nick Woolf
Chief Executive Officer
info@auscann.com.au
+61 8 6305 0705

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way medicinal cannabis is dispensed today by making standardised, controlled dose products, providing educational support to healthcare professionals and generating clinical evidence that is accessible to patients, physicians and healthcare providers. AusCann is developing a pipeline of proprietary differentiated cannabinoid-based pharmaceutical products. The Company's first product, a hard-shell capsule, based on the proprietary Neuvis® platform, was successfully launched in Australia in 2020 and is available under special access provisions for medicines.